Archivum Immunologiae et Therapiae Experimentalis

, Volume 57, Issue 3, pp 189–198

Dendritic cell-based cancer immunotherapies

  • Shin-ichiro Fujii
  • Takuya Takayama
  • Miki Asakura
  • Kaori Aki
  • Koji Fujimoto
  • Kanako Shimizu
Review

DOI: 10.1007/s00005-009-0025-x

Cite this article as:
Fujii, S., Takayama, T., Asakura, M. et al. Arch. Immunol. Ther. Exp. (2009) 57: 189. doi:10.1007/s00005-009-0025-x
  • 227 Views

Abstract

Because of their unique role in linking the innate and adaptive immune systems, dendritic cells (DCs) have been a logical focus for novel immunotherapies. However, strategies employing active immunization with ex vivo generated and antigen–pulsed DCs have shown limited efficacy in clinical trials. These past approaches did not take into account the complex interactions between cells of the innate immune system and DCs during DC maturation, antigen processing, and presentation to naïve T cells. By better understanding the natural sequence of events occurring in vivo during an effective immune response, we can tailor antitumor immunotherapeutic strategies to augment aspects of this response from the activation of innate immune cells to antigen uptake and DC maturation to priming of naïve T cells and, ultimately, to the establishment of antitumor immunity. Current DC vaccination strategies utilize a number of methods to recapitulate the cascade of events that culminate in a protective antitumor immune response.

Keywords

dendritic cells (DCs)adjuvantex vivo DC therapyin vivo DC therapyimmunotherapy

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2009

Authors and Affiliations

  • Shin-ichiro Fujii
    • 1
  • Takuya Takayama
    • 2
  • Miki Asakura
    • 1
  • Kaori Aki
    • 1
  • Koji Fujimoto
    • 3
  • Kanako Shimizu
    • 1
    • 4
  1. 1.Research Unit for Cellular Immunotherapy, Research Center for Allergy and Immunology (RCAI)Institute of Physical and Chemical Research (RIKEN), Yokohama RIKENYokohama, KanagawaJapan
  2. 2.Division of Cancer GenomicsCancer Institute (Japanese Foundation for Cancer Research)TokyoJapan
  3. 3.NTT West Kyushu Hospital, KumamotoKumamotoJapan
  4. 4.Research Unit for Therapeutic Model, Research Center for Allergy and Immunology (RCAI)Institute of Physical and Chemical Research (RIKEN)Yokohama, KanagawaJapan